ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
06 avr. 2023 08h30 HE
|
ContraFect Corporation
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism of Action of CF-370 YONKERS, N.Y., April 06, 2023 ...
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
18 avr. 2022 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference
13 avr. 2022 07h00 HE
|
MeMed
MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference Haifa, Israel;...
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
19 juil. 2021 07h31 HE
|
ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
12 juil. 2021 08h29 HE
|
Summit Therapeutics Inc.
Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European...
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
01 juil. 2021 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research...
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
11 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
27 janv. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
14 avr. 2019 07h42 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 ...
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
10 avr. 2019 02h00 HE
|
Centauri Therapeutics Limited
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) UK, 10 April 2019: Centauri Therapeutics (“Centauri”), an immunotherapy...